USPTO serial 99726259
WUXITECAN-2
Reviewed by CopyMark Law Group
Status 681
- Filing date
- Status date
- Registration date
- —
- Examiner
- HALL, MICHAEL E
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with WUXITECAN-2?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Candice Reder
Candice Reder Ice Miller LLP600 Superior Ave EastCleveland, OH 44114United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Active chemical ingredients for use in the manufacture of antineoplastic pharmaceuticals containing a topoisomerase I inhibitor payload pharmaceuticals; Chemical reagents, other than for medical or veterinary purpose; Biochemical catalysts; Biological preparations for use in the manufacture of antineoplastic pharmaceuticals containing a topoisomerase I inhibitor payload pharmaceuticals; Chemical preparations for scientific purposes, other than for medical or veterinary use; Heterocyclic compounds; Chemical preparations for use in the manufacture of antineoplastic pharmaceuticals containing a topoisomerase I inhibitor payload pharmaceuticals; Antibody reagents used for the detection of antigens in cells and tissue, other than for medical or veterinary purposes | ACTIVE | — |
| 005 | antineoplastic pharmaceuticals containing a topoisomerase I inhibitor payload pharmaceutical preparations for inhibiting tumors; antineoplastic pharmaceuticals containing a topoisomerase I inhibitor payload pharmaceutical products for the prevention and treatment of cancer; Biological preparations for the treatment of cancer; Biological preparations for use in cell cultures for medical purposes; Chemical reagents for medical or veterinary purposes; Chemical reagents for medical purposes; Antibodies for medical purposes; Biologics in the nature of cells for the treatment of cancer | ACTIVE | — |
| 040 | custom manufacture of antineoplastic pharmaceuticals containing a topoisomerase I inhibitor payload pharmaceuticals; Custom manufacturing of antineoplastic pharmaceuticals containing a topoisomerase I inhibitor payload pharmaceuticals; Manufacturing services for others in the field of antineoplastic pharmaceuticals containing a topoisomerase I inhibitor payload antibody drug conjugates and intermediates thereof; Custom manufacture of antineoplastic pharmaceuticals containing a topoisomerase I inhibitor payload pharmaceutical preparations, biomedical preparations, drug conjugates, anti-body drug conjugates, chemical reagents; Biomanufacturing for others of antineoplastic pharmaceuticals containing a topoisomerase I inhibitor payload pharmaceuticals using biological organisms in the manufacturing process | ACTIVE | — |
| 042 | Pharmaceutical research and development; Research and development in the pharmaceutical and biotechnology fields; Development of pharmaceutical preparations and medicines; Pharmaceutical drug development services; Research and development services of new pharmaceutical products; Research and development of antibody-drug conjugates; Research and development of conjugated antibodies; Product development consulting in the field of pharmaceuticals, anti-bodies, conjugated antibodies, chemical reagents; Product development for others; Biomedical research services; Scientific research in the nature of conducting clinical trials for others in the field of new pharmaceutical development | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 29, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 30, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 21, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 21, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 21, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 13, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 13, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 13, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 6, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 4, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 26, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Mar 26, 2026 | NWAP | NEW APPLICATION ENTERED | — |